Gene therapies to treat rheumatoid arthritis have evolved slowly, but one is ready to move into human trials and an ...

Medically reviewed by Soma Mandal, MD Petechiae are tiny red, purple, or brown spots on your skin, inside of your mouth, or ...

Treatment for sickle cell disease, the most common inherited blood disorder in Kenya, has been approved for use in England for older children and adults with a severe form of the disease.The treatment ...

More than one-quarter of blood or marrow transplant survivors developed cutaneous malignant neoplasms, according to study results.Researchers identified several risk factors, including older age, ...

During a live event, Andrew Kuykendall, MD, discussed management of anemia before and during use of JAK inhibitor for ...

Breakthrough research and investor enthusiasm prompted Cullinan Therapeutics to redirect one of its cancer programs toward ...

Joan Vassos has shared an update on ex Gerry Turner’s cancer, as well the status of their relationship after their split on ...

A study showed that using measurable residual disease (MRD) to guide ibrutinib-venetoclax therapy significantly improved ...

X4 Pharmaceuticals is laying off 30% of its staff and halting preclinical R&D as the immune system specialist channels its resources into recently approved rare disease drug mavorixafor.

About Y-mAbs Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, radioimmunotherapy and antibody-based therapeutic cancer products. The ...

In the latest study, researchers found the main genetic mutations in renal cell cancer, possibly by using artificial intelligence (AI). The scientists injected mRNA vaccine made against proteins ...

January 2025 kicked off with a wave of impactful biotech deals, setting the stage for an exciting year of innovation.